Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies.
Illiano M, Colinard M, Taque S, Mallon B, Larue C, Laithier V, Vérité-Goulard C, Sudour-Bonnange H, Faure-Conter C, Coze C, Aerts I, De Maricourt CD, Paillard C, Branchereau S, Brugières L, Fresneau B.
Illiano M, et al. Among authors: sudour bonnange h.
Hepatol Int. 2022 Feb;16(1):125-134. doi: 10.1007/s12072-021-10251-1. Epub 2021 Sep 10.
Hepatol Int. 2022.
PMID: 34506008